Reviewing GeneDx (NASDAQ:WGS) & Cannlabs (OTCMKTS:CANL)

Cannlabs (OTCMKTS:CANL) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Earnings & Valuation

This table compares Cannlabs and GeneDx”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cannlabs	N/A	N/A	N/A	N/A	N/A
GeneDx	$305.45 million	13.29	-$52.29 million	$0.09	1,560.44

Cannlabs has higher earnings, but lower revenue than GeneDx.

Risk and Volatility

Cannlabs has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cannlabs and GeneDx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cannlabs	0	0	0	0	0.00
GeneDx	1	3	7	0	2.55

GeneDx has a consensus price target of $134.78, suggesting a potential downside of 4.03%. Given Cannlabs’ higher probable upside, equities analysts clearly believe Cannlabs is more favorable than GeneDx.

Insider & Institutional Ownership

61.7% of GeneDx shares are owned by institutional investors. 29.6% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Cannlabs and GeneDx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cannlabs	N/A	N/A	N/A
GeneDx	0.52%	20.22%	11.89%

Summary

GeneDx beats Cannlabs on 9 of the 10 factors compared between the two stocks.

About Cannlabs

CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. was incorporated in 2010 and is based in Denver, Colorado.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.